# NCT03993249 (NCT03993249)

> Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03993249
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Hellenic GenitoUrinary Cancer Group
- Conditions: Bladder Cancer
- Interventions: Nivolumab; chemoradiotherapy
- Enrollment: 78
- Primary outcome: Locoregional control rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03993249